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The discovery of aquaporin (AQP) has made a great impact on life sciences. AQPs are a family of homologous water channels widely
distributed in plants, unicellular organisms, invertebrates, and vertebrates. So far, 13 AQPs have been identified in human. AQP3, 7, 9, and 10 are
subcategorized as aquaglyceroporins which permeabilize glycerol as well as water. Many investigators have demonstrated that AQPs play a
crucial role in maintaining water homeostasis, but the physiological significance of some AQPs as a glycerol channel is not fully understood.
Adipose tissue is a major source of glycerol and glycerol is one of substrates for gluconeogenesis. This review focuses on recent studies of
glycerol metabolism through aquaglyceroporins, and briefly discusses the importance of glycerol channel in adipose tissues and liver.
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In adipocytes, lipogenesis and lipolysis are observed in
response to whole body energy balance. Adipose tissue stores
triglyceride (TG) in case of excess of nutrition, while adipose
tissue provides free fatty acid (FFA) and glycerol to the energy
expenditure organs by hydrolyzing TG under starvation and/or
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of human beings, starvation is a great matter of life or death.
Adipocytes play a crucial role in energy supply under starvation
to maintain energy homeostasis, and contribute to the survival
of human beings during long starvation periods. However, at the
present day, over-nutrition and lack of exercise cause over-
accumulation of fat, especially in industrial countries [2–4].
This socio-environmental change causes and increases life-
style-related diseases, such as diabetes, hyperlipidemia, hyper-
tension, and atherosclerosis, that are commonly recognized as
metabolic syndrome [5,6]. Fat accumulation, especially intra-
abdominal fat deposits, is considered to be located in the
pathological upstream of metabolic syndrome [7–10]. Consis-
tent with the concept of metabolic syndrome, many investiga-
tors have tried to clarify the underlying mechanism of obesity.
To find a novel therapy for metabolic syndrome, it is necessary
to focus on the biology and science of adipocyte, that authors
named as “Adiposcience”. Recent progress in this field shows
that the pathogenesis of metabolic syndrome is associated with
adipocyte dysfunction [11].
Adipocytes hydrolyze TG and rapidly liberate FFA and
glycerol into the circulation. It is presumed that glycerol
channel in adipocytes prevent acute rise in intracellular osmotic
pressure when glycerol production is rapidly increased during
lipolysis. However, the underlying mechanism responsible for
glycerol release from adipocytes remains elusive. We identified
aquaporin (AQP) 7 from the human adipose tissue cDNA
library in 1997 [12].Fig. 1. A model illustrating lipogenesis and lipolysis in adipocytes. Under lipogenic co
and transfers glucose transporter 4 (GLUT4) to the plasma membrane, and takes g
(Glycerol-3-P). Insulin also activates lipoprotein lipase (LPL) located on the cell
intestine-derived chylomicron (CM) and liver-derived very low-density lipoprotein (V
P are esterified into triglyceride (TG). Under lipolytic conditions, sympathetic ner
adrenergic receptors located on the surface of adipocytes. Activation of adrenergic
hydrolyzing TG to FFA and glycerol, to the lipid droplets, while related stimuli m
bloodstream and utilized for thermogenesis and gluconeogenesis, respectively. Mo
cascade. Thus, long-term regulation of AQP7 is under the control of insulin while
pathways of AQP7 assure the efficient release of glycerol from adipocytes under faIn this review, we assess research conducted on adipose-
specific glycerol channel AQP7 and liver-specific glycerol
channel AQP9. We also discuss the relation between glycerol
metabolism and AQPs, focusing mainly on analysis of AQP7-
deficient mice.
2. Characteristics of adipocytes
Adipose tissue is considered an energy storage organ where
lipogenesis and lipolysis occur in response to whole body
energy balance (Fig. 1). Adipocytes have a unique feature;
lipid droplets occupy a large part of the intracellular region,
while the nucleus and cytosome are located in the periphery. In
comparison, the nucleus is located in the center of cell in other
tissue cells. Thus, adipocytes are morphologically character-
ized by TG accumulation.
β-cells in the pancreas secret insulin in response to a rise in
plasma glucose concentration at feeding state. Insulin acts on
adipose tissues as well as skeletal muscles, transfers glucose
transporter 4 (GLUT4) to plasma membrane, and takes glucose
into cell [13]. In addition, insulin activates lipoprotein lipase
(LPL) located on the cell surface of the vascular endothelium.
LPL removes fatty acids from intestine-derived chylomicron
(CM) and liver-derived very low-density lipoprotein (VLDL),
and then fatty acids are taken into adipocytes [14]. In adipocytes,
glycerol-3-phosphate (glycerol-3-P) converted from glucose and
fatty acids are esterified into TG. Fatty acid binding protein
(FABP) [15], fatty acid translocase (FAT) [16,17], and fatty acidnditions, insulin binds to the insulin receptor located on the surface of adipocytes
lucose into the cell. Intracellular glucose is converted to glycerol-3-phosphate
surface of the vascular endothelium. Activated-LPL removes fatty acids from
LDL), and then fatty acids are taken into adipocytes. Fatty acids and glycerol-3-
ves are activated and catecholamines are increased. Catecholamines stimulate
receptors translocates hormone sensitive lipase (HSL), which is a key enzyme
oves AQP7 to the plasma membrane. FFA and glycerol are released into the
reover, AQP7 mRNA levels are elevated by the decrease of insulin signaling
short-term regulation is under catecholamines. These two different regulatory
sting conditions.
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transporters in adipocytes.
In contrast to the feeding state, exercise and/or fasting
induces lipolysis in adipocytes [19]. Fasting stimulates sympa-
thetic nerves and elevates catecholamines, such as adrenaline
and noradrenalin, which in turn stimulate adrenergic receptor
located on the surface of adipocytes. Activation of adrenergic
receptor results in converting adenosine 5′-triphosphate (ATP)
to cyclic adenosine monophosphate (cAMP). Elevation of
intracellular cAMP activates hormone-sensitive lipase (HSL)
by phosphorylation. Phosphorylated-HSL hydrolyzes TG to
FFA and glycerol, and both are released into the bloodstream.
FFA and glycerol are utilized for thermogenesis and gluconeo-
genesis, respectively.
3. Adipose-specific glycerol channel; AQP7
3.1. Molecular cloning and tissue distribution of AQP7
We analyzed the gene expression profile of human visceral
and subcutaneous fat to clarify the molecular mechanism of
obesity-related diseases [20]. We identified a novel comple-
mentary DNA (cDNA) belonging to the AQP family during
this analysis, and named it aquaporin adipose (AQPap)
because its mRNA is expressed abundantly in adipose tissues
and adipocytes [12]. AQPap is a human counterpart of AQP7
that was independently cloned from rat testis by another group
at the same time [21]. Fig. 2 demonstrates the tissue
distribution of AQP7 in mice. AQP7 is highly expressed in
white adipose tissue (WAT), brown adipose tissue (BAT), and
testis. Furthermore, a weak expression of AQP7 is also
observed in the heart, skeletal muscles, and kidneys. As shown
in Fig. 2, the transcript of testis AQP7 forms short length in
comparison with the other organ AQP7, which is accounted
for the different lengths of the untranslated region of cDNA
locating at 3′-end [22].
3.2. Functional analysis and regulation of AQP7 in adipocytes
AQP7-expressing Xenopus oocytes gain water and glycerol
permeability [23]. This gain of function is inhibited by HgCl2Fig. 2. Tissue distributions of mouse AQP7 and AQP9. Shown is northern
blotting analysis of various tissues. Ten micrograms of total RNA was
electrophoresed on 1% agarose/formaldehyde gel and transferred to nylon
membranes. The membrane was hybridized with the indicated cDNA probe
labeled with [α-32P]dCTP. The hybridized membrane was exposed to X-ray
film. WAT, white adipose tissue; BAT, brown adipose tissue.and its inhibition is recovered by 2-mercaptoethanol, similar to
the other AQPs. This result indicates that AQP7 can be
subcategorized as an aquaglyceroporin, which enhance perme-
ation of glycerol, in addition to water. In mammals, AQP3, 7, 9,
and 10 are considered to belong to aquaglyceroporin family at
present. Interestingly, Escherichia coli has one aquaporin
(AqpZ) and one aquaglyceroporin (GlpF) [24]. These findings
indicate that glycerol channel is required even in E. coli and that
glycerol is an essential substance for living.
AQP7 mRNA expression increases in parallel with
adipocytes differentiation of 3T3-L1 cells. Glycerol release
into the media also increases in parallel with AQP7 mRNA
levels in differentiating 3T3-L1 adipocytes [23]. Peroxisome
proliferator activated receptor γ (PPARγ) is a master regulator
of adipocytes differentiation and regulates several adipose-
specific genes at the transcriptional level. PPARγ forms a
heterodimer with retinoic acid X receptor α (RXRα), and
binds to peroxisome proliferator response element (PPRE) site.
The PPRE site is identified in the promoter region of AQP7
gene based on analysis of the mouse AQP7 gene. Hetero-
dimers of PPARγ and RXRα bind to the PPRE site of AQP7
promoter and up-regulates AQP7 mRNA expression in
adipocytes [25]. Furthermore, administration of thiazolidine-
diones (TZDs), which are insulin-sensitizing agents and
exogenous PPARγ ligands, increase AQP7 mRNA levels in
3T3-L1 adipocytes and in adipose tissues of mice. The precise
mechanism of TZD in ameliorating insulin resistance is not
fully understood. To clarify whether the TZD-induced adipose
AQP7 is related to the amelioration of insulin resistance,
requires further studies in the future.
AQP7 mRNA levels are reduced by feeding and increased by
fasting in parallel with plasma glycerol levels [23]. These
nutrition-related changes in AQP7 and plasma glycerol are the
opposites of plasma insulin levels. In fact, in 3T3-L1
adipocytes, insulin suppresses AQP7 mRNA levels in a dose-
and time-dependent manners. The insulin negative response
element (IRE) is identified in the promoter region of AQP7 gene
[22]. This result indicates that AQP7 mRNA expression is
closely regulated by insulin at the transcriptional level.
Furthermore, glucose-6-phosphatase (G6Pase) and phospho-
enolpyruvate carboxykinase (PEPCK), which are key enzymes
of gluconeogenesis, also contain IRE in their promoter regions.
Insulin also suppresses the mRNA levels of G6Pase and
PEPCK. Taken together, plasma glycerol levels are partly
determined by insulin through adipose AQP7, and suggests that
adipose AQP7 may be associated with glucose metabolism.
In 3T3-L1 adipocytes, AQP7 is localized at the periphery
of the nucleus in steady state. However, AQP7 translocates to
the plasma membrane following adrenaline stimulation,
which induces lipolysis [23]. Adrenaline does not affect
AQP7gene expression. Adrenaline elevates intracellular
cAMP levels through adrenergic receptor and then activates
protein kinase A (PKA). Interestingly, similar results are
observed in AQP2, which is a key water channel of kidney.
Briefly, AQP2 exists in the principal cells of the renal
collecting duct. Immunogold electron microscopy studies
showed that very little of AQP2 protein is found in the apical
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AQP2 protein exists in the membranes of intracellular
vesicles. However, AQP2 protein relocates to the apical
plasma membrane when collecting duct cells are stimulated
by vasopressin, an anti-diuretic hormone released from the
brain [26]. Vasopressin binds to V2 receptor at the basolateral
membrane of the renal collecting duct causing activation of a
G-coupled adenylylcyclase cascade that results in phosphor-
ylation of AQP2 by PKA [27]. The phosphorylation site of
AQP2 is located at residue 256 on the C-terminus of its
protein. Phosphorylated-AQP2 moves to the apical plasma
membrane. These results suggest that AQP7, as well as
AQP2, may be phosphorylated by PKA under the activation
of adrenergic receptor. Database analysis indicates the six
prospective sites of PKA phosphorylation in both human and
mouse AQP7. It is necessary to determine the phosphoryla-
tion site of AQP7 in the future.
Fig. 1 right panel shows a model illustrating the regulation of
AQP7 at fasting state. Collectively, catecholamine stimuli
translocate HSL to the lipid droplets and moves AQP7 to the
plasma membrane. Phosphorylated-HSL hydrolyzes TG to fatty
acids and glycerol in cooperation with perillipin, which is
another key molecule in lipolysis. Moreover, reduced insulin
signal results in up-regulation of AQP7 mRNA levels. Finally,
glycerol produced by hydrolysis in adipocytes is released into
the bloodstream through AQP7.
3.3. Human genetic mutation in AQP7 gene
Human AQP7 gene mutation was reported in searching 160
Japanese subjects [28]. In that study, three types of missense
mutation were identified; R12C (a C→T substitution at
nucleotide 206 in exon 3 led to substitution of arginine with
cysteine at position 12, which resides in the N-terminal
cytoplasmic domain): 1 subject, V59L (a G→C substitution
at nucleotide 347 in exon 4 caused substitution of valine with
leucine at position 59, which resides in the 1st bilayer-spanning
domain): 13 subjects, G264V (a G→T substitution at
nucleotide 963 in exon 8 led to substitution of glycine with
valine at position 264, which resides in the 6th bilayer-spanning
domain): 6 subjects. Functional analysis using Xenopus oocytes
shows that the permeability of water and glycerol is disturbed in
oocytes expressing G264V mutant protein while those expres-
sing R12C or V59L mutant proteins retain water and glycerol
permeability. G264V mutation is located in 6th bilayer-
spanning domain. Structural analysis of AQP1 shows that the
conserved GxxxGxxxG motif in the 3rd and 6th bilayer-
spanning domain is important for functional conformation of
AQP family protein; glycine can be sometimes replaced by
alanine in the motif [29,30]. In the 6th bilayer-spanning domain
of human AQP7, A260, G264, and G268 form this motif.
Functional defect in the G264V mutant might be caused by
disturbance of this motif. The subjects with homozygous
mutation of G264V showed a similar exercise-induced rise in
plasma noradrenalin compared to healthy volunteers whereas
the increase in plasma glycerol was apparently disturbed during
exercise [28]. This result indicates that AQP7 may be a crucialmolecule for maintaining plasma glycerol levels in vivo.
However, obesity and diabetes were not observed in subjects
with homozygous mutation of G264V. Further analysis of
human AQP7 gene and/or frequency of AQP7 mutation in
subjects with the metabolic syndrome should be performed in
the future.
3.4. Role of AQP7 in other organs
Our group discovered AQP7 during genomic analysis of
human adipose tissue, and at the same time another group
identified AQP7 from the rat testis [21]. AQP7 is also expressed
in human sperms. Lack of AQP7 expression in sperms is
observed in several male infertile subjects. Other studies
demonstrated that sperm AQP7 is associated with the capacity
of sperm movement [31]. Immunohistochemical analysis shows
that AQP7 is also expressed in the proximal tubules of the
kidney. AQP7-deficient mice exhibit hyperglycerourea, sug-
gesting that AQP7 is involved in glycerol re-absorption in the
kidney [32].
As shown in Fig. 2, skeletal muscles express small amounts
of AQP7. Recent immunohistochemical studies using anti-
AQP7 antibody demonstrated immunoreactivity at the myofi-
ber surface of type 1 and type 2 fibers in human muscles and
of type 2 fibers in mouse muscles [33]. The role of AQP4 has
been extensively investigated in skeletal muscles [34,35].
AQP4 is reduced in the skeletal muscle of patients with
Duchenne dystrophy [36,37], of mdx mice [38,39], and of
patients with amyotrophic lateral sclerosis [40]. The nerve
activity is thought to control the expression of AQP4 in
skeletal muscles. While the function of AQP4 has been
clarified in skeletal muscles, the physiological role of AQP7 in
skeletal muscles has remained unclear. Fig. 2 also demon-
strates that heart expresses AQP7. Fatty acids and/or glucose
are widely recognized as energy source in the heart. Why does
AQP7 exist as a glycerol channel in the heart? What is the role
of glycerol in the heart? There are currently no published
studies on the functional role of AQP7 in the heart. Further
investigations of skeletal muscle and/or heart AQP7 should be
performed in the future.
4. Liver-specific glycerol channel; AQP9
4.1. Molecular cloning and tissue distribution of AQP9
AQP9 was independently identified in human leukocytes
[41] and rat liver [42,43]. Northern blotting analysis identified
human AQP9 expression in liver, leukocyte, lung, and spleen
[41]. In rat, AQP9 mRNA is found in liver, testis, brain [42], and
lung [43]. As in Fig. 2, AQP9 is also highly expressed in mouse
liver and testis. In hepatocytes, immunohistochemistry showed
that AQP9 is localized at the sinusoidal plasma membrane [44].
4.2. Functional analysis and regulation of AQP9 in liver
Rat AQP9-expressing Xenopus oocytes exhibit water and
glycerol permeability [41]. A series of studies on Xenopus
Fig. 3. Coordinated regulation of adipose AQP7 and liver AQP9 during fasting
and feeding states. (A) A model illustrating the regulation of AQPs under fasted
state. Fasting induces lipolysis in adipocytes and gluconeogenesis in liver. As
shown in Fig. 1, AQP7 mRNA levels are elevated, AQP7 protein translocates to
the plasma membrane, and AQP7 serves as an efficient release of glycerol in
adipocytes under fasting conditions. Fasting also increases AQP9 mRNA levels
in liver, the increased portal glycerol directly flows into the liver, and AQP9 may
contribute to the entry of glycerol into hepatocytes. In the liver, glycerol is one of
substrates for gluconeogenesis. The glycerol cascade from adipose tissue to liver
is maintained by the coordinated regulation of AQP7 and AQP9 under fasting
state. (B) A model illustrating the regulation of AQPs under fed state. After
feeding, the increased plasma insulin makes a metabolic switch from lipolysis to
lipogenesis in adipocytes, and suppresses glucose production from liver.
Adipose AQP7 mRNA levels are reduced under feeding state, while glucose
transporter 4 (GLUT4) translocates to the plasma membrane and takes glucose
into adipocytes. Adipocytes store triglyceride (TG) by esterificating glucose and
fatty acids. Portal glycerol levels decrease in parallel with the reduction of
adipose AQP7 and liver AQP9 mRNAs.
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mannitol, sorbitol, and uracil. In consistent with this finding,
another group found that rat AQP9 is permeable to water,
glycerol and urea [43]. These results indicate a broad selectivity
of rat AQP9. However, another group found the AQP9-induced
permeability to be restricted to water and urea in human [41].
Thus, there are conflicting results regarding AQP9-induced
permeability between rat and human. Future studies could
provide further information based on the physiological function
of AQP9 and can be designed to generate and analyze AQP9
knockout mice, and/or analyze human genetic mutation in
AQP9 gene.
Arsenic trioxide uptake was examined with yeast expressing
mammalian AQP7 or AQP9 as well as in oocytes expressing
these proteins [45]. The results of these studies showed that
AQP7 and AQP9 may be the major routes of arsenite uptake
into mammalian cells. Arsenic trioxide is uncharged at neutral
pH values and is very toxic. Clinical features of greatest concern
in arsenic poisoning include hepatocellular damage and
hepatocellular carcinoma.
Intra-abdominal visceral fat accumulates mainly in the
mesentery. The anatomical distribution of intra-abdominal
visceral fat indicates that substances released from the visceral
fat directly flow into the liver via the portal vein. FFA derived
from visceral fat during lipolysis elevates liver acyl-coenzyme
A synthetase (ACS) and microsomal triglyceride transfer
protein (MTP) mRNA levels, and reduces degradation of
apolipoprotein B (ApoB). These changes induce the release of
ApoB from the liver and increase plasma triglyceride
concentrations. Hypertriglyceridemia, which is often observed
in subjects with visceral fat accumulation, is partly accounted
for the increase in FFA derived from adipose tissues [46].
Glycerol, which is another product from adipose TG during
lipolysis, directly flows into the liver via portal vein and
become substrate for gluconeogenesis. AQP9 is considered as
the sole glycerol channel in liver and is localized at the
sinusoidal plasma membrane facing the portal vein [44].
Taken together, AQP9 may act as a channel of glycerol uptake
in the liver (Fig. 3A). AQP9 mRNA levels increase by fasting
and decrease by feeding [47]. These changes in AQP9 mRNA
are similar to those of glycerol kinase, which is a key enzyme
involved in the conversion of glycerol to glycerol-3-phos-
phate, and PEPCK, which is a key enzyme for gluconeogen-
esis. Insulin suppresses AQP9 mRNA levels in time- and
dose-dependent manners in H4IIE hepatocytes. Promoter
analysis demonstrates that insulin reduces AQP9 mRNA via
IRE locating at −496/−502 promoter region. Administration of
streptozotocin (STZ) results in increased AQP9 mRNA [47]
and protein [48] levels in insulin-insufficient mice.
4.3. Coordination of adipose and liver glycerol channels
In feeding state, a rise in plasma insulin concentration
results in suppression of lipolysis and the mRNA expression
of adipose AQP7, and results in reduced glycerol release
from adipocytes. Feeding also reduces liver AQP9 mRNA
and glycerol-based gluconeogenesis (Fig. 3B). However, highadipose AQP7 and liver AQP9 mRNA levels are observed in
obese and insulin-resistant animals in spite of hyperinsuline-
mia. These animals show increased glycerol release from
adipose tissues in parallel with the increase of AQP7 mRNA,
and also increased glycerol levels in portal vein. Finally, the
high glycerol levels in portal vein causes gluconeogenesis
and results in hyperglycemia through the pathological
induction of liver AQP9 [47]. Considered collectively,
physiological and pathological coordinated regulation of
organ-specific glycerol channels, adipose AQP7 and liver
AQP9, may contribute to glycerol and glucose metabolism in
vivo (Fig. 3).
Fig. 4. Schematic presentation of the physiological role of AQP7 based on the
analysis of AQP7 knockout mice. (A) The summary of younger mice. Under
starvation, AQP7 knockout (AQP7-KO) mice exhibit impairment of plasma
glycerol elevation and result in severe hypoglycemia in comparison with wild-
type (WT) mice. There is evidence that AQP7 acts as an adipose glycerol
channel in vivo and that adipose-derived glycerol is a significant substrate for
gluconeogenesis. (B) The summary and photo of older mice. AQP7-KO mice
develop obesity accompanied by adipocyte hypertrophy after 12 weeks of age.
Photo in the right panel shows WT and KO mice at 40 weeks of age. The high
intracellular glycerol contents induce the enzymatic activity of glycerol kinase in
adipose tissues of AQP7-KO mice at young age. Glycerol kinase promotes re-
esterification of glycerol and accelerates triglyceride (TG) accumulation in
adipocytes. Moreover, AQP7-KO mice exhibit whole body insulin resistance
associated with obesity.
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5.1. Adipose-derived glycerol and gluconeogenesis through
AQP7
Recently, we generated and analyzed AQP7 knockout
(AQP7-KO) mice [49]. AQP7-KO mice exhibit lower plasma
and portal glycerol concentrations under fasting state than wild-
type (WT) mice under the same condition. Administration of
β3-adrenergic agonist, which specifically effects on adipocytes
and enhances lipolysis, results in impaired plasma glycerol
elevation in AQP7-KO mice but does not modulate the normal
increase of plasma FFA in both WT and AQP7-KO mice.
Similar results are obtained in in vitro 3T3-L1 adipocytes
introduced by RNAi. Briefly, adrenaline-mediated glycerol
release is significantly disturbed in AQP7-knockdown 3T3-L1
adipocytes, while adrenaline-mediated FFA release from
AQP7-knockdown adipocytes is similar to that of 3T3-L1
adipocytes transfected with control-RNAi. Longer starvation
test demonstrated that AQP7-KO mice exhibit impaired plasma
glycerol elevation associated with severe hypoglycemia in
comparison with WT mice. The results of a series of studies
indicate that AQP7 acts as an adipose glycerol channel in vivo
and that adipose-derived glycerol is a significant substrate for
gluconeogenesis (Fig. 4A).
5.2. Adipocytes dysfunction in AQP7-deficient cells
There is no difference in body weight of WT and AQP7-KO
mice at young age, but AQP7-KO mice become obese after 12
weeks of age [50]. Adipose tissue weights of AQP7-KOmice are
significantly heavier than WT mice at 20 weeks of age.
Histological analysis shows an increase in hypertrophic
adipocytes in epididymal WAT of AQP7-KO mice. Moreover,
AQP7-KO mice exhibit whole body insulin resistance associ-
ated with obesity (Fig. 4B). Recently, Hara-Chikuma et al. [51]
also reported increased number of hypertrophic adipocytes in
AQP7-KO mice, although the body weights of their AQP7-KO
mice were similar to those of WT mice. The difference of
phenotypes may be accounted for the genetic background of
mice.
Food intake, rectal temperature, and oxygen consumption of
AQP7-KO mice are similar to WT mice at young age. At young
age, there are no apparent differences in adipose mRNA levels,
which are related to adipogenesis, lipogenesis, lipolysis, and
thermogenesis, between AQP7-KO and WT mice. However,
intracellular glycerol contents of AQP7-KO mice are signifi-
cantly higher than those of WT mice at young age. A recent
study reported that glycerol induces conformational changes and
enzymatic activity of glycerol kinase, which is a key enzyme in
the conversion of glycerol to glycerol-3-phosphate [52].
Actually, the activity of adipose glycerol kinase of AQP7-KO
mice is elevated before development of obesity. Previous study
indicated that over-expression of glycerol kinase promotes re-
esterification of glycerol and accelerates TG accumulation in
adipocytes [53]. Knockdown of AQP7 in 3T3-L1 adipocytes
increases intracellular glycerol contents, elevates glycerol kinaseactivities, enhances oleic acid uptake, and finally results in TG
accumulation [50].
In summary, deficiency of adipose AQP7 influences on
not only glycerol metabolism but also glucose metabolism
in vivo.
6. Conclusions and outlook
The discovery of AQP has made a great impact on life
sciences. Structural and functional analyses of AQPs indicate
that AQPs do not only permeate water. Novel metabolic
mechanisms have been clarified by the demonstration that
some AQPs act as glycerol channels. Investigation of AQPs-
dependent glycerol metabolism should help the design of novel
therapeutic strategies for metabolic syndrome. Future studies
1010 T. Hibuse et al. / Biochimica et Biophysica Acta 1758 (2006) 1004–1011should further refine our understanding of the association
between glycerol metabolism and AQPs.
References
[1] T.G. Ramsay, Fat cells, Endocrinol. Metab. Clin. North Am. 25 (1996)
847–870.
[2] B.B. Kahn, J.S. Flier, Obesity and insulin resistance, J. Clin. Invest. 106
(2000) 473–481.
[3] B.M. Spiegelman, J.S. Flier, Obesity and the regulation of energy balance,
Cell 104 (2001) 531–543.
[4] J.M. Friedman, Modern science versus the stigma of obesity, Nat. Med. 10
(2004) 563–569.
[5] Executive Summary of The Third Report of The National Cholesterol
Education Program (NCEP) Expert Panel on Detection, Evaluation, and
Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel
III), JAMA 285 (2001) 2486–2497.
[6] P. Zimmet, K.G. Alberti, J. Shaw, Global and societal implications of the
diabetes epidemic, Nature 414 (2001) 782–787.
[7] S. Fujioka, Y. Matsuzawa, K. Tokunaga, S. Tarui, Contribution of intra-
abdominal fat accumulation to the impairment of glucose and lipid
metabolism in human obesity, Metabolism 36 (1987) 54–59.
[8] H. Kanai, Y. Matsuzawa, K. Kotani, Y. Keno, T. Kobatake, Y. Nagai, S.
Fujioka, K. Tokunaga, S. Tarui, Close correlation of intra-abdominal fat
accumulation to hypertension in obese women, Hypertension 16 (1990)
484–490.
[9] T. Nakamura, K. Tokunaga, I. Shimomura, M. Nishida, S. Yoshida, K.
Kotani, A.H. Islam, Y. Keno, T. Kobatake, Y. Nagai, et al., Contribution of
visceral fat accumulation to the development of coronary artery disease in
non-obese men, Atherosclerosis 107 (1994) 239–246.
[10] S. Yamashita, T. Nakamura, I. Shimomura, M. Nishida, S. Yoshida, K.
Kotani, K. Kameda-Takemuara, K. Tokunaga, Y. Matsuzawa, Insulin
resistance and body fat distribution, Diabetes Care 19 (1996) 287–291.
[11] T. Funahashi, T. Nakamura, I. Shimomura, K. Maeda, H. Kuriyama, M.
Takahashi, Y. Arita, S. Kihara, Y. Matsuzawa, Role of adipocytokines on
the pathogenesis of atherosclerosis in visceral obesity, Intern. Med. 38
(1999) 202–206.
[12] H. Kuriyama, S. Kawamoto, N. Ishida, I. Ohno, S. Mita, Y. Matsuzawa, K.
Matsubara, K. Okubo, Molecular cloning and expression of a novel human
aquaporin from adipose tissue with glycerol permeability, Biochem.
Biophys. Res. Commun. 241 (1997) 53–58.
[13] P.R. Shepherd, B.B. Kahn, Glucose transporters and insulin action—
Implications for insulin resistance and diabetes mellitus, N. Engl. J. Med.
341 (1999) 248–257.
[14] J.R. Mead, S.A. Irvine, D.P. Ramji, Lipoprotein lipase: structure, function,
regulation, and role in disease, J. Mol. Med. 80 (2002) 753–769.
[15] W. Stremmel, G. Strohmeyer, F. Borchard, S. Kochwa, P.D. Berk,
Isolation and partial characterization of a fatty acid binding protein in
rat liver plasma membranes, Proc. Natl. Acad. Sci. U. S. A. 82 (1985)
4–8.
[16] A. Ibrahimi, Z. Sfeir, H. Magharaie, E.Z. Amri, P. Grimaldi, N.A.
Abumrad, Expression of the CD36 homolog (FAT) in fibroblast cells:
effects on fatty acid transport, Proc. Natl. Acad. Sci. U. S. A. 93 (1996)
2646–2651.
[17] K.Motojima, P. Passilly, J.M. Peters, F.J. Gonzalez, N. Latruffe, Expression
of putative fatty acid transporter genes are regulated by peroxisome
proliferator-activated receptor alpha and gamma activators in a tissue- and
inducer-specific manner, J. Biol. Chem. 273 (1998) 16710–16714.
[18] J.E. Schaffer, H.F. Lodish, Expression cloning and characterization of a
novel adipocyte long chain fatty acid transport protein, Cell 79 (1994)
427–436.
[19] C. Londos, D.L. Brasaemle, C.J. Schultz, D.C. Adler-Wailes, D.M. Levin,
A.R. Kimmel, C.M. Rondinone, On the control of lipolysis in adipocytes,
Ann. N. Y. Acad. Sci. 892 (1999) 155–168.
[20] K. Maeda, K. Okubo, I. Shimomura, K. Mizuno, Y. Matsuzawa, K.
Matsubara, Analysis of an expression profile of genes in the human
adipose tissue, Gene 190 (1997) 227–235.[21] K. Ishibashi, M. Kuwahara, Y. Gu, Y. Kageyama, A. Tohsaka, F. Suzuki, F.
Marumo, S. Sasaki, Cloning and functional expression of a new water
channel abundantly expressed in the testis permeable to water, glycerol,
and urea, J. Biol. Chem. 272 (1997) 20782–20786.
[22] K. Kishida, I. Shimomura, H. Kondo, H. Kuriyama, Y. Makino, H.
Nishizawa, N. Maeda, M. Matsuda, N. Ouchi, S. Kihara, Y. Kurachi, T.
Funahashi, Y. Matsuzawa, Genomic structure and insulin-mediated
repression of the aquaporin adipose (AQPap), adipose-specific glycerol
channel, J. Biol. Chem. 276 (2001) 36251–36260.
[23] K. Kishida, H. Kuriyama, T. Funahashi, I. Shimomura, S. Kihara, N.
Ouchi, M. Nishida, H. Nishizawa, M. Matsuda, M. Takahashi, K. Hotta, T.
Nakamura, S. Yamashita, Y. Tochino, Y. Matsuzawa, Aquaporin adipose, a
putative glycerol channel in adipocytes, J. Biol. Chem. 275 (2000)
20896–20902.
[24] P. Agre, L.S. King, M. Yasui, W.B. Guggino, O.P. Ottersen, Y. Fujiyoshi,
A. Engel, S. Nielsen, Aquaporin water channels—From atomic structure to
clinical medicine, J. Physiol. (London) 542 (2002) 3–16.
[25] K. Kishida, I. Shimomura, H. Nishizawa, N. Maeda, H. Kuriyama, H.
Kondo, M. Matsuda, H. Nagaretani, N. Ouchi, K. Hotta, S. Kihara, T.
Kadowaki, T. Funahashi, Y. Matsuzawa, Enhancement of the aquaporin
adipose gene expression by a peroxisome proliferator-activated receptor
gamma, J. Biol. Chem. 276 (2001) 48572–48579.
[26] S. Nielsen, C.L. Chou, D. Marples, E.I. Christensen, B.K. Kishore, M.
A. Knepper, Vasopressin increases water permeability of kidney
collecting duct by inducing translocation of aquaporin-CD water
channels to plasma membrane, Proc. Natl. Acad. Sci. U. S. A. 92
(1995) 1013–1017.
[27] M. Kuwahara, K. Fushimi, Y. Terada, L. Bai, F. Marumo, S. Sasaki,
cAMP-dependent phosphorylation stimulates water permeability of
aquaporin-collecting duct water channel protein expressed in Xenopus
oocytes, J. Biol. Chem. 270 (1995) 10384–10387.
[28] H. Kondo, I. Shimomura, K. Kishida, H. Kuriyama, Y. Makino, H.
Nishizawa, M. Matsuda, N. Maeda, H. Nagaretani, S. Kihara, Y. Kurachi,
T. Nakamura, T. Funahashi, Y. Matsuzawa, Human aquaporin adipose
(AQPap) gene. Genomic structure, promoter analysis and functional
mutation, Eur. J. Biochem. 269 (2002) 1814–1826.
[29] K. Murata, K. Mitsuoka, T. Hirai, T. Walz, P. Agre, J.B. Heymann, A.
Engel, Y. Fujiyoshi, Structural determinants of water permeation through
aquaporin-1, Nature 407 (2000) 599–605.
[30] J.B. Heymann, A. Engel, Structural clues in the sequences of the
aquaporins, J. Mol. Biol. 295 (2000) 1039–1053.
[31] K. Saito, Y. Kageyama, Y. Okada, S. Kawakami, K. Kihara, K. Ishibashi,
S. Sasaki, Localization of aquaporin-7 in human testis and ejaculated
sperm: possible involvement in maintenance of sperm quality, J. Urol. 172
(2004) 2073–2076.
[32] E. Sohara, T. Rai, J.I. Miyazaki, A.S. Verkman, S. Sasaki, S. Uchida,
Defective water and glycerol transport in the proximal tubules of AQP7
knockout mice, Am. J. Physiol.: Renal. Physiol. 289 (2005)
F1195–F1200.
[33] Y. Wakayama, M. Inoue, H. Kojima, T. Jimi, S. Shibuya, H. Hara, H.
Oniki, Expression and localization of aquaporin 7 in normal skeletal
myofiber, Cell Tissue Res. 316 (2004) 123–129.
[34] A. Frigeri, G.P. Nicchia, J.M. Verbavatz, G. Valenti, M. Svelto, Expression
of aquaporin-4 in fast-twitch fibers of mammalian skeletal muscle, J. Clin.
Invest. 102 (1998) 695–703.
[35] A. Frigeri, G.P. Nicchia, B. Nico, F. Quondamatteo, R. Herken, L. Roncali,
M. Svelto, Aquaporin-4 deficiency in skeletal muscle and brain of
dystrophic mdx mice, FASEB J. 15 (2001) 90–98.
[36] A. Frigeri, G.P. Nicchia, S. Repetto, M. Bado, C. Minetti, M. Svelto,
Altered aquaporin-4 expression in human muscular dystrophies: a
common feature? FASEB J. 16 (2002) 1120–1122.
[37] Y. Wakayama, T. Jimi, M. Inoue, H. Kojima, M. Murahashi, T. Kumagai,
S. Yamashita, H. Hara, S. Shibuya, Reduced aquaporin 4 expression in the
muscle plasma membrane of patients with Duchenne muscular dystrophy,
Arch. Neurol. 59 (2002) 431–437.
[38] J.W. Liu, Y. Wakayama, M. Inoue, S. Shibuya, H. Kojima, T. Jimi, H.
Oniki, Immunocytochemical studies of aquaporin 4 in the skeletal muscle
of mdx mouse, J. Neurol. Sci. 164 (1999) 24–28.
1011T. Hibuse et al. / Biochimica et Biophysica Acta 1758 (2006) 1004–1011[39] R.H. Crosbie, S.A. Dovico, J.D. Flanagan, J.S. Chamberlain, C.L. Ownby,
K.P. Campbell, Characterization of aquaporin-4 in muscle and muscular
dystrophy, FASEB J. 16 (2002) 943–949.
[40] T. Jimi, Y. Wakayama, Y. Matsuzaki, H. Hara, M. Inoue, S. Shibuya,
Reduced expression of aquaporin 4 in human muscles with amyotrophic
lateral sclerosis and other neurogenic atrophies, Pathol. Res. Pract. 200
(2004) 203–209.
[41] K. Ishibashi, M. Kuwahara, Y. Gu, Y. Tanaka, F. Marumo, S. Sasaki,
Cloning and functional expression of a new aquaporin (AQP9)
abundantly expressed in the peripheral leukocytes permeable to water
and urea, but not to glycerol, Biochem. Biophys. Res. Commun. 244
(1998) 268–274.
[42] H. Tsukaguchi, C. Shayakul, U.V. Berger, B. Mackenzie, S. Devidas, W.B.
Guggino, A.N. van Hoek, M.A. Hediger, Molecular characterization of a
broad selectivity neutral solute channel, J. Biol. Chem. 273 (1998)
24737–24743.
[43] S.B. Ko, S. Uchida, S. Naruse, M. Kuwahara, K. Ishibashi, F. Marumo, T.
Hayakawa, S. Sasaki, Cloning and functional expression of rAOP9L a new
member of aquaporin family from rat liver, Biochem. Mol. Biol. Int. 47
(1999) 309–318.
[44] M. Elkjaer, Z. Vajda, L.N. Nejsum, T. Kwon, U.B. Jensen, M. Amiry-
Moghaddam, J. Frokiaer, S. Nielsen, Immunolocalization of AQP9 in liver,
epididymis, testis, spleen, and brain, Biochem. Biophys. Res. Commun.
276 (2000) 1118–1128.
[45] Z. Liu, J. Shen, J.M. Carbrey, R. Mukhopadhyay, P. Agre, B.P. Rosen,
Arsenite transport by mammalian aquaglyceroporins AQP7 and AQP9,
Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 6053–6058.
[46] H. Kuriyama, S. Yamashita, I. Shimomura, T. Funahashi, M. Ishigami, K.
Aragane, K. Miyaoka, T. Nakamura, K. Takemura, Z. Man, K. Toide, N.
Nakayama, Y. Fukuda, M.C. Lin, J.R. Wetterau, Y. Matsuzawa, Enhanced
expression of hepatic acyl-coenzyme A synthetase and microsomal
triglyceride transfer protein messenger RNAs in the obese and hyper-triglyceridemic rat with visceral fat accumulation, Hepatology 27 (1998)
557–562.
[47] H. Kuriyama, I. Shimomura, K. Kishida, H. Kondo, N. Furuyama, H.
Nishizawa, N. Maeda, M. Matsuda, H. Nagaretani, S. Kihara, T.
Nakamura, Y. Tochino, T. Funahashi, Y. Matsuzawa, Coordinated
regulation of fat-specific and liver-specific glycerol channels, aquaporin
adipose and aquaporin 9, Diabetes 51 (2002) 2915–2921.
[48] J.M. Carbrey, D.A. Gorelick-Feldman, D. Kozono, J. Praetorius, S.
Nielsen, P. Agre, Aquaglyceroporin AQP9: solute permeation and
metabolic control of expression in liver, Proc. Natl. Acad. Sci. U. S. A.
100 (2003) 2945–2950.
[49] N. Maeda, T. Funahashi, T. Hibuse, A. Nagasawa, K. Kishida, H.
Kuriyama, T. Nakamura, S. Kihara, I. Shimomura, Y. Matsuzawa,
Adaptation to fasting by glycerol transport through aquaporin 7 in adipose
tissue, Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 17801–17806.
[50] T. Hibuse, N. Maeda, T. Funahashi, K. Yamamoto, A. Nagasawa, W.
Mizunoya, K. Kishida, K. Inoue, H. Kuriyama, T. Nakamura, T. Fushiki, S.
Kihara, I. Shimomura, Aquaporin 7 deficiency is associated with
development of obesity through activation of adipose glycerol kinase,
Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 10993–10998.
[51] M. Hara-Chikuma, E. Sohara, T. Rai, M. Ikawa, M. Okabe, S. Sasaki, S.
Uchida, A.S. Verkman, Progressive adipocyte hypertrophy in aquaporin-7-
deficient mice: adipocyte glycerol permeability as a novel regulator of fat
accumulation, J. Biol. Chem. 280 (2005) 15493–15496.
[52] J.I. Yeh, V. Charrier, J. Paulo, L. Hou, E. Darbon, A. Claiborne, W.G. Hol,
J. Deutscher, Structures of enterococcal glycerol kinase in the absence and
presence of glycerol: correlation of conformation to substrate binding and a
mechanism of activation by phosphorylation, Biochemistry 43 (2004)
362–373.
[53] H.P. Guan, Y. Li, M.V. Jensen, C.B. Newgard, C.M. Steppan, M.A. Lazar,
A futile metabolic cycle activated in adipocytes by antidiabetic agents,
Nat. Med. 8 (2002) 1122–1128.
